Mylan Speciality Lp Drug Patent Portfolio
Mylan Speciality Lp owns 4 orange book drugs protected by 13 US patents Given below is the list of Mylan Speciality Lp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7645801 | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) | 24 Jul, 2027 | Active |
| US8168620 | Combination of azelastine and steroids | 24 Aug, 2026 | Active |
| US8168620 | Combination of azelastine and steroids | 24 Feb, 2026 | Active |
| US7449012 | Automatic injector | 11 Sep, 2025 | Active |
| US7794432 | Automatic injector with kickback attenuation | 11 Sep, 2025 | Active |
| US8048035 | Automatic injector with needle cover | 11 Sep, 2025 | Active |
| US8870827 | Automatic injector | 11 Sep, 2025 | Active |
| US9586010 | Automatic injector with needle cover | 11 Sep, 2025 | Active |
| US8163723 | Combination of azelastine and steroids | 29 Feb, 2024 | Expired |
| US9259428 | Combination of azelastine and fluticasone for nasal administration | 13 Dec, 2023 | Expired |
| US8163723 | Combination of azelastine and steroids | 29 Aug, 2023 | Expired |
| US9259428 | Combination of azelastine and fluticasone for nasal administration | 13 Jun, 2023 | Expired |
| US9901585 | Combination of azelastine and fluticasone for nasal administration | 13 Jun, 2023 | Expired |
Latest Legal Activities on Mylan Speciality Lp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mylan Speciality Lp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 03 Jun, 2024 | US8168620 (Litigated) |
|
Expire Patent
Critical
| 27 May, 2024 | US8163723 (Litigated) |
|
Expire Patent
Critical
| 25 Mar, 2024 | US9259428 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Dec, 2023 | US8168620 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 11 Dec, 2023 | US8163723 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 09 Oct, 2023 | US9259428 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Apr, 2023 | US8048035 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Apr, 2023 | US8048035 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Apr, 2022 | US8870827 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Apr, 2022 | US8870827 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Mar, 2022 | US7794432 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Mar, 2022 | US7794432 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Aug, 2021 | US9901585 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 Jun, 2021 | US7645801 |
|
Email Notification
Critical
| 07 May, 2021 | US9586010 |
Mylan Speciality Lp's Drug Patent Litigations
Mylan Speciality Lp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 2008, against patent number US7645801. The petitioner , challenged the validity of this patent, with Bala VENKATARAMAN et al as the respondent. Click below to track the latest information on how companies are challenging Mylan Speciality Lp's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8163723 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US8168620 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US9259428 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US9901585 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US8168620 | February, 2017 |
Terminated-Settled
(21 May, 2018)
| Cipla Limited | Argentum Pharmaceuticals LLC |
| US7645801 | April, 2008 |
Decision
(08 Dec, 2008)
| Bala VENKATARAMAN et al | |
Mylan Speciality Lp Drug Patents' Oppositions Filed in EPO
Mylan Speciality Lp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 14, 2010, by Glaxo Group Limited. This opposition was filed on patent number EP03738280A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP10155967A | Jan, 2021 | Keilitz Haines & Partner Patentanwälte PartGmbB | Granted and Under Opposition |
| EP10155967A | Apr, 2020 | ALK-ABELLO A/S | Granted and Under Opposition |
| EP05783727A | Nov, 2016 | ALK-ABELLO A/S | Revoked |
| EP05783727A | Nov, 2016 | Merck Patent GmbH | Revoked |
| EP05783727A | Oct, 2016 | Meridian Medical Technologies, Inc. | Revoked |
| EP09173753A | Jul, 2016 | Merck Patent GmbH | Patent maintained as amended |
| EP09075100A | Apr, 2016 | Sanovel IIaç San. ve Tic. A.S. | Revoked |
| EP10194414A | Feb, 2015 | Feldmeier, Jürgen | Revoked |
| EP10194414A | Nov, 2014 | ALK-ABELLO A/S | Revoked |
| EP09075101A | Oct, 2014 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Revoked |
| EP09075101A | Oct, 2014 | Sanovel IIaç San. ve Tic. A.S. | Revoked |
| EP03738280A | Jan, 2010 | Glaxo Group Limited | Revoked |
Mylan Speciality Lp's Family Patents
Mylan Speciality Lp Drug List
Given below is the complete list of Mylan Speciality Lp's drugs and the patents protecting them.
1. Dymista
Dymista is protected by 7 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8168620
(Pediatric)
| Combination of azelastine and steroids |
24 Aug, 2026
(1 year, 4 months from now)
| Active |
| US8168620 | Combination of azelastine and steroids |
24 Feb, 2026
(10 months from now)
| Active |
| US8163723
(Pediatric)
| Combination of azelastine and steroids |
29 Feb, 2024
(1 year, 1 month ago)
| Expired |
| US9259428
(Pediatric)
| Combination of azelastine and fluticasone for nasal administration |
13 Dec, 2023
(1 year, 3 months ago)
| Expired |
| US8163723 | Combination of azelastine and steroids |
29 Aug, 2023
(1 year, 7 months ago)
| Expired |
| US9259428 | Combination of azelastine and fluticasone for nasal administration |
13 Jun, 2023
(1 year, 9 months ago)
| Expired |
| US9901585 | Combination of azelastine and fluticasone for nasal administration |
13 Jun, 2023
(1 year, 9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dymista's drug page
2. Epipen
Epipen is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7449012 | Automatic injector |
11 Sep, 2025
(5 months from now)
| Active |
| US7794432 | Automatic injector with kickback attenuation |
11 Sep, 2025
(5 months from now)
| Active |
| US8048035 | Automatic injector with needle cover |
11 Sep, 2025
(5 months from now)
| Active |
| US8870827 | Automatic injector |
11 Sep, 2025
(5 months from now)
| Active |
| US9586010 | Automatic injector with needle cover |
11 Sep, 2025
(5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epipen's drug page
3. Epipen Jr.
Epipen Jr. is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7449012 | Automatic injector |
11 Sep, 2025
(5 months from now)
| Active |
| US7794432 | Automatic injector with kickback attenuation |
11 Sep, 2025
(5 months from now)
| Active |
| US8048035 | Automatic injector with needle cover |
11 Sep, 2025
(5 months from now)
| Active |
| US8870827 | Automatic injector |
11 Sep, 2025
(5 months from now)
| Active |
| US9586010 | Automatic injector with needle cover |
11 Sep, 2025
(5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epipen Jr.'s drug page
4. Sfrowasa
Sfrowasa is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7645801 | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
24 Jul, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sfrowasa's drug page